Mapping the Use of Ketamine in Treatment-Resistant Depression and Other Psychiatric Disorders: A Scoping Review of Practice Patterns, Efficacy, and Patient Demographic Trends.
American journal of therapeutics Amna M Aslam, Kenneth Shinozuka, Owen Muir et al. 5 citations
Ketamine is increasingly used for treatment-resistant depression, especially after FDA approval of esketamine, yet significant barriers to access remain. Intravenous administration is the most common method, with intramuscular and sublingual routes emerging. Patients are predominantly middle-aged (36-64 years old), and financial obstacles due to limited insurance coverage are notable. Access is limited in rural areas, and private clinics offer more flexible treatment than hospitals. The absence of long-term outcome data and variability in protocols underscore the need for standardization and further research.